Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

melanosomeEVimmune

Financiado

Cerrado

Melanosomes as cancer immune modulators: a novel paradigm in melanoma immunity

Despite remarkable progress in treating melanoma, the most lethal of human skin cancers, 50% of patients are treatment-resistant, with most experiencing disease recurrence. Our recent unpublished clinical and experimental findings... ver más

31/12/2028

TAU

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-01

ERC-2022-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

TAU

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EVasion Evasion of antitumor immunity and immunotherapy by melanoma... 173K€ Cerrado

IMMUNO-TEX Overcoming resistance to immunotherapy: Immunostimulatory tu... 2M€ Cerrado

UNPACK PD-L1 Molecular mechanism and inhibition of extracellular vesicle... 176K€ Cerrado

KILNEV Killing Senescent Cells as a Novel Method to Eliminate Nevi 166K€ Cerrado

BMDCMET Innate and adaptive immune cell contribution to the pre meta... 184K€ Cerrado

PRE2021-098562 CARACTERIZACION DE MECANISMOS MOLECULARES IMPLICADOS EN DESA... 101K€ Cerrado

Duración del proyecto: 59 meses Fecha Inicio: 2024-01-01
Fecha Fin: 2028-12-31

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite remarkable progress in treating melanoma, the most lethal of human skin cancers, 50% of patients are treatment-resistant, with most experiencing disease recurrence. Our recent unpublished clinical and experimental findings uncover new, yet to be explored, melanosome contributions to cancer immunity unique to melanoma. Melanoma retains, for mostly unknown reasons, the ability of its origin to produce melanosomes, lineage-specific large extracellular vesicles (EVs) containing melanin. Surprisingly, our preliminary findings indicate that melanosomes bind and block T-cell activity in a T-cell receptor/antigen-dependent manner; melanosomes carry a neoantigen signature that is distinct from their cell of origin; and can be recycled by stoma cells, with each type endowing the melanosomes with a distinct signature, which may modulate, upon engulfment by macrophages, the latter’s phenotype in relation to melanoma. Given our novel findings and body of literature that strongly suggest an immune role for melanosomes, we here propose to comprehensively explore, for the first time, melanosomes’ effect on melanoma immunity in three directions: melanosomes’ interaction with T-cells (Aim 1), influence on melanoma immune recognition (Aim 2) and interaction with macrophages (Aim 3). This will be achieved by a strong research framework involving new experimental tools, fresh human samples, and cutting-edge in-vivo, molecular, cellular and computational models. While of tremendous complexity and scale, this project is set to offer new perspectives on melanoma progression and response to therapy. Further, our novel EV concepts will greatly advance the EV field and can also be applied to other physiological systems. Our project will also offer the scientific community new experimental tools and omics data on melanoma EVs and immunity. Finally, our project will provide new potential therapeutic means to overcome melanoma immunotherapy-resistance and block melanoma progression.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores